Daunorubicin
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Daunorubicin |
| DrugBank ID | DB00694 |
| Brand Names (EU) | Daunorubicin |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.82% |
Approved Indication (EMA)
See EMA product information
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | acute lymphoblastic/lymphocytic leukemia | 99.82% | DL |
| 2 | Hodgkins lymphoma | 99.81% | DL |
| 3 | vertebral anomalies and variable endocrine and T-cell dysfunction | 99.80% | DL |
| 4 | ganglioneuroblastoma (disease) | 99.80% | DL |
| 5 | neuroblastoma | 99.78% | DL |
| 6 | ALK-positive large B-cell lymphoma | 99.78% | DL |
| 7 | adenosarcoma | 99.77% | DL |
| 8 | retroperitoneal neoplasm | 99.77% | DL |
| 9 | small cell lung carcinoma | 99.76% | DL |
| 10 | primary pulmonary lymphoma | 99.76% | DL |
| 11 | pulmonary blastoma | 99.76% | DL |
| 12 | well-differentiated fetal adenocarcinoma of the lung | 99.75% | DL |
| 13 | upper aerodigestive tract neoplasm | 99.74% | DL |
| 14 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | 99.73% | DL |
| 15 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | 99.73% | DL |
| 16 | leukemia, lymphocytic, susceptibility to | 99.72% | DL |
| 17 | obsolete Hodgkin’s granuloma | 99.71% | DL |
| 18 | uterine ligament adenosarcoma | 99.69% | DL |
| 19 | myeloid leukemia | 99.67% | DL |
| 20 | osteopathia striata with cranial sclerosis | 99.63% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.